Exports to US market

Even though their revenue is lower than Mobilia's

Most furniture company listed are worth double.

Post removed.Why?

Post removed.Why?

High shares lock by moratorium

The perfect stock to limit up on listing date

Like anyone cares

Post removed.Why?

Shhhhhh

Post removed.Why?

Shhhh

Where can simply cancel wan

Post removed.Why?

Post removed.Why?

Post removed.Why?

If not you are juts talking lubbish

Invest Malaysia show us your dcf calculation

Post removed.Why?

这里垃圾丑的废物当自己是人的太多了。连死狗上的寄生物都不如的兽物。我说错了。他们连灵魂都缺了 只不过是无生无活的东西。你走过这些可怜又恶劣的东西肯定不觉它的存在。不小心踩它，踢它都不觉。因为它们比空气中的二氧化碳更渺小，渺小一万陪。我们做人的太幸运了，该多多体谅这些垃圾丑废物不如死狗上的寄生物还比空气中的二氧化碳小万陪，可怜它们是上天其中最无价的创物。

所以，如果在这而遇见了胡说八道说手套股的坏话请不要被激动，反正，写这些废话的东西只不过是垃圾丑废物不如死狗上的寄生物还比空气中的二氧化碳小万陪，你非要和这些无价无尊严的小废物辩论？它们的意见还比沟渠里臭鼠上的寄生物的意见更不重要。

Show this message to glove shit talkers

这里垃圾丑的废物当自己是人的太多了。连死狗上的寄生物都不如的兽物。我说错了。他们连灵魂都缺了 只不过是无生无活的东西。你走过这些可怜又恶劣的东西肯定不觉它的存在。不小心踩它，踢它都不觉。因为它们比空气中的二氧化碳更渺小，渺小一万陪。我们做人的太幸运了，该多多体谅这些垃圾丑废物不如死狗上的寄生物还比空气中的二氧化碳小万陪，可怜它们是上天其中最无价的创物。

所以，如果在这而遇见了胡说八道说手套股的坏话请不要被激动，反正，写这些废话的东西只不过是垃圾丑废物不如死狗上的寄生物还比空气中的二氧化碳小万陪，你非要和这些无价无尊严的小废物辩论？它们的意见还比沟渠里臭鼠上的寄生物的意见更不重要。

这里垃圾丑的废物当自己是人的太多了。连死狗上的寄生物都不如的兽物。我说错了。他们连灵魂都缺了 只不过是无生无活的东西。你走过这些可怜又恶劣的东西肯定不觉它的存在。不小心踩它，踢它都不觉。因为它们比空气中的二氧化碳更渺小，渺小一万陪。我们做人的太幸运了，该多多体谅这些垃圾丑废物不如死狗上的寄生物还比空气中的二氧化碳小万陪，可怜它们是上天其中最无价的创物。

所以，如果在这而遇见了胡说八道说手套股的坏话请不要被激动，反正，写这些废话的东西只不过是垃圾丑废物不如死狗上的寄生物还比空气中的二氧化碳小万陪，你非要和这些无价无尊严的小废物辩论？它们的意见还比沟渠里臭鼠上的寄生物的意见更不重要。

Buy in early first. Wait for the upcoming fantastic qrs

Retailers buying only. Where got big boys. When big boys come Kobay already RM 8, RM 1 billion company

Post removed.Why?

Post removed.Why?

Lol

Audi you are gambler turn long term bag holder. You are not an investor. You are a bag holder who doesn't know when to release

Post removed.Why?

Not far fetch to think they might clinch a project

But they did get the paynet project

No not digital license. Anyway, it is just rumor. I never believe rumors.

Got people say they got a big contract. But I don't believe.

Glove finish you sound like a stupid short term trader who lose money all the time.

If any wrongdoing is found, the analysts licenses should be revoked and JP Morgan should be fine

Why they abruptly start coverage on TG and issue a target price that is 30% of consensus estimate? This is absurd and warrants the deepest of investigations.

Should report JP Morgan to SC to investigate for market manipulating activities

It is extremely ridiculous for JP Morgan to use the cost of capital argument. The cost of capital argument only arises when you are planning to raise capital.
Now, if you have excess cash lying around, the proceeds should used to fund capital expenditure that generates returns over the hurdle rate. That is the right move.

To suggest that Topglove should instead borrow money and declare the cash as dividend is stupid. In effect, JP Morgan is calling for companies to raise debts to pay dividends.

This erroneous argument proves the two analyst at JP Morgan is not qualified to issue analyst reports and should have their license revoked.

Since those two analysts don't have the qualifications and qualities as stock analysts, I suppose they should join stockraixer and Pancut Gloves as commoners. Quit their jobs because they have no business in the investing world.

Stockraixer and Pancut Gloves, you guys don't have the qualifications to dissect this issue. Stay out of the argument because you are worse than layman.

It is extremely ridiculous for JP Morgan to use the cost of capital argument. The cost of capital argument only arises when you are planning to raise capital.
Now, if you have excess cash lying around, the proceeds should used to fund capital expenditure that generates returns over the hurdle rate. That is the right move.

To suggest that Topglove should instead borrow money and declare the cash as dividend is stupid. In effect, JP Morgan is calling for companies to raise debts to pay dividends.

This erroneous argument proves the two analyst at JP Morgan is not qualified to issue analyst reports and should have their license revoked.

Adding to Number 8. It is extremely ridiculous for JP Morgan to use the cost of capital argument. The cost of capital argument only arises when you are planning to raise capital.
Now, if you have excess cash lying around, the proceeds should used to fund capital expenditure that generates returns over the hurdle rate. That is the right move.

To suggest that Topglove should instead borrow money and declare the cash as dividend is stupid. In effect, JP Morgan is calling for companies to raise debts to pay dividends.

This erroneous argument proves the two analyst at JP Morgan is not qualified to issue analyst reports and should have their license revoked.

I hope this issue can be thoroughly investigated considering that they suddenly start coverage and immediately peg a valuation at 30% of consensus estimate

Where is their evidence that testing is on a downtrend? How is that possible when more than 600,000 cases have been detected each day, triple from September. With such a high number of cases, it is ridiculous to suggest mass testing has declined. Simple observation points to the contrary. JP Morgan must back their claim with solid evidence.

Secondly, since when does glove demand depend on testing? There are numerous other applications in battling covid that require gloves. There are strong evidence that glove shortage will extend to 2022. How can JP Morgan issue a report saying otherwise without providing strong evidence of their own? It is clear that incoming glove supply will come far short of meeting glove demand in the next 2 years. Not providing a good reason for stating otherwise is very irresponsible.

Thirdly, JP Morgan using palm oil companies as comparison is extremely irresponsible and a weak evidence. Palm Oil supply cannot be controlled due to weather and the sheer number of palm oil companies making it hard to plan for supply. What the analysts had offered is grossly inaccurate and unacceptable. They clearly have not done due diligence.

Lastly, Topglove has already guided ASP to rise 30% next quarter. The pricing power is very much in the hands of glove manufacturers. JP Morgan suggested glove prices has peaked in September. This is grossly inaccurate and shows it has been disregarding market research. In fact, Topglove has recorded far higher ASP in the two months following September, and is going to hike it by a further 30% in the next quarter. The reality is far too different from JP Morgan's poorly concluded estimates. It is obvious gloves are much needed in much higher quantities than before.

All these points to poor analysis that is not done in good faith, without due diligence. Action should be taken to maintain the integrity of our capital markets to prevent manipulation.

Where is their evidence that testing is on a downtrend? How is that possible when more than 600,000 cases have been detected each day, triple from September. With such a high number of cases, it is ridiculous to suggest mass testing has declined. Simple observation points to the contrary. JP Morgan must back their claim with solid evidence.

Secondly, since when does glove demand depend on testing? There are numerous other applications in battling covid that require gloves. There are strong evidence that glove shortage will extend to 2022. How can JP Morgan issue a report saying otherwise without providing strong evidence of their own? It is clear that incoming glove supply will come far short of meeting glove demand in the next 2 years. Not providing a good reason for stating otherwise is very irresponsible.

Thirdly, JP Morgan using palm oil companies as comparison is extremely irresponsible and a weak evidence. Palm Oil supply cannot be controlled due to weather and the sheer number of palm oil companies making it hard to plan for supply. What the analysts had offered is grossly inaccurate and unacceptable. They clearly have not done due diligence.

Lastly, Topglove has already guided ASP to rise 30% next quarter. The pricing power is very much in the hands of glove manufacturers. JP Morgan suggested glove prices has peaked in September. This is grossly inaccurate and shows it has been disregarding market research. In fact, Topglove has recorded far higher ASP in the two months following September, and is going to hike it by a further 30% in the next quarter. The reality is far too different from JP Morgan's poorly concluded estimates. It is obvious gloves are much needed in much higher quantities than before.

All these points to poor analysis that is not done in good faith, without due diligence. Action should be taken to maintain the integrity of our capital markets to prevent manipulation.

Where is their evidence that testing is on a downtrend? How is that possible when more than 600,000 cases have been detected each day, triple from September. With such a high number of cases, it is ridiculous to suggest mass testing has declined. Simple observation points to the contrary. JP Morgan must back their claim with solid evidence.

Secondly, since when does glove demand depend on testing? There are numerous other applications in battling covid that require gloves. There are strong evidence that glove shortage will extend to 2022. How can JP Morgan issue a report saying otherwise without providing strong evidence of their own? It is clear that incoming glove supply will come far short of meeting glove demand in the next 2 years. Not providing a good reason for stating otherwise is very irresponsible.

Thirdly, JP Morgan using palm oil companies as comparison is extremely irresponsible and a weak evidence. Palm Oil supply cannot be controlled due to weather and the sheer number of palm oil companies making it hard to plan for supply. What the analysts had offered is grossly inaccurate and unacceptable. They clearly have not done due diligence.

Lastly, Topglove has already guided ASP to rise 30% next quarter. The pricing power is very much in the hands of glove manufacturers. JP Morgan suggested glove prices has peaked in September. This is grossly inaccurate and shows it has been disregarding market research. In fact, Topglove has recorded far higher ASP in the two months following September, and is going to hike it by a further 30% in the next quarter. The reality is far too different from JP Morgan's poorly concluded estimates. It is obvious gloves are much needed in much higher quantities than before.

All these points to poor analysis that is not done in good faith, without due diligence. Action should be taken to maintain the integrity of our capital markets to prevent manipulation.

Where is their evidence that testing is on a downtrend? How is that possible when more than 600,000 cases have been detected each day, triple from September. With such a high number of cases, it is ridiculous to suggest mass testing has declined. Simple observation points to the contrary. JP Morgan must back their claim with solid evidence.

Secondly, since when does glove demand depend on testing? There are numerous other applications in battling covid that require gloves. There are strong evidence that glove shortage will extend to 2022. How can JP Morgan issue a report saying otherwise without providing strong evidence of their own? It is clear that incoming glove supply will come far short of meeting glove demand in the next 2 years. Not providing a good reason for stating otherwise is very irresponsible.

Thirdly, JP Morgan using palm oil companies as comparison is extremely irresponsible and a weak evidence. Palm Oil supply cannot be controlled due to weather and the sheer number of palm oil companies making it hard to plan for supply. What the analysts had offered is grossly inaccurate and unacceptable. They clearly have not done due diligence.

Lastly, Topglove has already guided ASP to rise 30% next quarter. The pricing power is very much in the hands of glove manufacturers. JP Morgan suggested glove prices has peaked in September. This is grossly inaccurate and shows it has been disregarding market research. In fact, Topglove has recorded far higher ASP in the two months following September, and is going to hike it by a further 30% in the next quarter. The reality is far too different from JP Morgan's poorly concluded estimates. It is obvious gloves are much needed in much higher quantities than before.

All these points to poor analysis that is not done in good faith, without due diligence. Action should be taken to maintain the integrity of our capital markets to prevent manipulation.

Where is their evidence that testing is on a downtrend? How is that possible when more than 600,000 cases have been detected each day, triple from September. With such a high number of cases, it is ridiculous to suggest mass testing has declined. Simple observation points to the contrary. JP Morgan must back their claim with solid evidence.

Secondly, since when does glove demand depend on testing? There are numerous other applications in battling covid that require gloves. There are strong evidence that glove shortage will extend to 2022. How can JP Morgan issue a report saying otherwise without providing strong evidence of their own? It is clear that incoming glove supply will come far short of meeting glove demand in the next 2 years. Not providing a good reason for stating otherwise is very irresponsible.

Thirdly, JP Morgan using palm oil companies as comparison is extremely irresponsible and a weak evidence. Palm Oil supply cannot be controlled due to weather and the sheer number of palm oil companies making it hard to plan for supply. What the analysts had offered is grossly inaccurate and unacceptable. They clearly have not done due diligence.

Lastly, Topglove has already guided ASP to rise 30% next quarter. The pricing power is very much in the hands of glove manufacturers. JP Morgan suggested glove prices has peaked in September. This is grossly inaccurate and shows it has been disregarding market research. In fact, Topglove has recorded far higher ASP in the two months following September, and is going to hike it by a further 30% in the next quarter. The reality is far too different from JP Morgan's poorly concluded estimates. It is obvious gloves are much needed in much higher quantities than before.

All these points to poor analysis that is not done in good faith, without due diligence. Action should be taken to maintain the integrity of our capital markets to prevent manipulation.

Report Jeffrey Ng and YY Cheah to SC, both analyst at JP Morgan. Request for an investigation into these two individuals for market manipulating activities. What is the reason they start coverage on glove sector and immediately give an extremely low tp at 30% of consensus? If any hankypanky, their license should be revoked asap.